Skip to main content
Figure 2 | Journal of Hematology & Oncology

Figure 2

From: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

Figure 2

Oroxylin A downregulates the protein and mRNA expression of p53-related glycolytic pathway components. (A) MCF-7 and HCT116 cells were treated with oroxylin A (100 and 200 μΜ) for 48 h. Western blot assays were performed for the p53-targeted gene products p53, TIGAR, PGM, and GLUT4. (B) H1299 cells were transfected with a cDNA clone targeting wt-p53 or with a non-targeting vector, then incubated with 200 μM oroxylin A for 48 h. Western blot assays were performed for the p53-targeted gene products TIGAR, PGM, and GLUT4. (C) The gene expressions of p53, MDM2, and p53-targeted genes were detected by Quantitative RT-PCR. (D) MCF-7 and HCT116 were transfected with siRNA targeting wt-p53 or with a non-targeting control siRNA, then incubated with 200 μM oroxylin A for 48 h. Western blot assays were performed for the p53-targeted gene products TIGAR, PGM, and GLUT4. All the Western Blot bands were quantified. Bars, SD; *p < 0.05 or **p < 0.01 versus non-treated control.

Back to article page